Products for Out-Licensing

Products Available for Out-Licensing

NAL develops novel dosage forms and proprietary drug delivery systems based on Company’s captive Drug Delivery System (“DDS”) technologies. NAL expects to partner with pharmaceutical companies for the development and commercialization of the NAL products in global markets.

The partial listing of NAL’s products is outlined below. As we have not disclosed the complete list of our proprietary DDS products under development, please write to us at [email protected] to know more about NAL’s products and partnering opportunities.

Weight Loss
 
Products Marketed or Under Development (Partial Listing)
Proposed US Filing
NAL3923 Semaglutide 1-Day Tablet
ANDA
NAL3925 Semaglutide 1-Week Injection
ANDA
NAL3929 Tirzepatide 1-Week Injection
ANDA
Top